Harmony Biosciences Reports Positive Bioequivalence Results for Pitolisant Gastro-Resistant Formulation

Reuters

2025/11/24

<a href="https://laohu8.com/S/HRMY">Harmony Biosciences</a> Reports Positive Bioequivalence Results for Pitolisant Gastro-Resistant Formulation

Harmony Biosciences Holdings Inc. announced positive results from a pivotal bioequivalence study evaluating its gastro-resistant (GR) formulation of pitolisant. The study demonstrated that the 17.8 mg pitolisant GR formulation is bioequivalent to the existing 17.8 mg WAKIX® (pitolisant) tablets, with comparable AUC and Cmax values. The company also reported that a dosing optimization study showed 100% of patients were able to initiate treatment at the therapeutic dose without the need for titration. No new safety or tolerability issues were observed in the studies. Harmony plans to submit a New Drug Application for pitolisant GR in early 2026, with a targeted PDUFA date in the first quarter of 2027. Results from these studies have already been announced.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251124261066) on November 24, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2585462974"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585462974\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585462974?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585462974","market":"us","top_or_hot":-1,"title":"Harmony Biosciences Reports Positive Bioequivalence Results for Pitolisant Gastro-Resistant Formulation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HRMY\">Harmony Biosciences</a> Reports Positive Bioequivalence Results for Pitolisant Gastro-Resistant Formulation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harmony Biosciences Holdings Inc. announced positive results from a pivotal bioequivalence study evaluating its gastro-resistant (GR) formulation of pitolisant. The study demonstrated that the 17.8 mg pitolisant GR formulation is bioequivalent to the existing 17.8 mg WAKIX® (pitolisant) tablets, with comparable AUC and Cmax values. The company also reported that a dosing optimization study showed 100% of patients were able to initiate treatment at the therapeutic dose without the need for titration. No new safety or tolerability issues were observed in the studies. Harmony plans to submit a New Drug Application for pitolisant GR in early 2026, with a targeted PDUFA date in the first quarter of 2027. Results from these studies have already been announced.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251124261066) on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harmony Biosciences Reports Positive Bioequivalence Results for Pitolisant Gastro-Resistant Formulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarmony Biosciences Reports Positive Bioequivalence Results for Pitolisant Gastro-Resistant Formulation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-24 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HRMY\">Harmony Biosciences</a> Reports Positive Bioequivalence Results for Pitolisant Gastro-Resistant Formulation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harmony Biosciences Holdings Inc. announced positive results from a pivotal bioequivalence study evaluating its gastro-resistant (GR) formulation of pitolisant. The study demonstrated that the 17.8 mg pitolisant GR formulation is bioequivalent to the existing 17.8 mg WAKIX® (pitolisant) tablets, with comparable AUC and Cmax values. The company also reported that a dosing optimization study showed 100% of patients were able to initiate treatment at the therapeutic dose without the need for titration. No new safety or tolerability issues were observed in the studies. Harmony plans to submit a New Drug Application for pitolisant GR in early 2026, with a targeted PDUFA date in the first quarter of 2027. Results from these studies have already been announced.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251124261066) on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL5wVlz2:1","article_id":"2585462974","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585462974","pubTimestamp":1763989520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Harmony Biosciences Holdings Inc. announced positive results from a pivotal bioequivalence study evaluating its gastro-resistant  formulation of pitolisant. The study demonstrated that the 17.8 mg pitolisant GR formulation is bioequivalent to the existing 17.8 mg WAKIX  tablets, with comparable AUC and Cmax values. The company also reported that a dosing optimization study showed 100% of patients were able to initiate treatment at the therapeutic dose without the need for titration. No new safety or tolerability issues were observed in the studies. Harmony plans to submit a New Drug Application for pitolisant GR in early 2026, with a targeted PDUFA date in the first quarter of 2027. Results from these studies have already been announced.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inter","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","HRMY":"Harmony Biosciences Holdings, Inc."},"translate_title":"Harmony Biosciences报告Pitolisant胃耐药制剂的积极生物等效性结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HRMY":0.9},"content_text":"Harmony Biosciences Reports Positive Bioequivalence Results for Pitolisant Gastro-Resistant Formulation\n    \n\n        Harmony Biosciences Holdings Inc. announced positive results from a pivotal bioequivalence study evaluating its gastro-resistant (GR) formulation of pitolisant. The study demonstrated that the 17.8 mg pitolisant GR formulation is bioequivalent to the existing 17.8 mg WAKIX® (pitolisant) tablets, with comparable AUC and Cmax values. The company also reported that a dosing optimization study showed 100% of patients were able to initiate treatment at the therapeutic dose without the need for titration. No new safety or tolerability issues were observed in the studies. Harmony plans to submit a New Drug Application for pitolisant GR in early 2026, with a targeted PDUFA date in the first quarter of 2027. Results from these studies have already been announced.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251124261066) on November 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}